1. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies. Kennedy VE, Savani BN, Greer JP, Kassim AA, Engelhardt BG, Goodman SA, Sengsayadeth S, Chinratanalab W, Jagasia M (2016) Biol Blood Marrow Transplant 22(10): 1801-1807
    › Primary publication · 27377900 (PubMed)
  2. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT. Fuji S, Rovó A, Ohashi K, Griffith M, Einsele H, Kapp M, Mohty M, Majhail NS, Engelhardt BG, Tichelli A, Savani BN (2016) Bone Marrow Transplant 51(8): 1041-9
    › Primary publication · 27042848 (PubMed)
  3. Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. Engelhardt BG, Paczesny S, Jung DK, Daguindau E, Jagasia M, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Yoder SM, Rock MT, Crowe JE (2016) Haematologica 101(5): e204-8
    › Primary publication · 26819055 (PubMed) · PMC5004357 (PubMed Central)
  4. Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials. Sengsayadeth S, Savani BN, Jagasia M, Goodman S, Greer JP, Chen H, Chinratanalab W, Kassim AA, Engelhardt BG (2014) Bone Marrow Transplant 49(2): 236-40
    › Primary publication · 24096824 (PubMed) · PMC3946331 (PubMed Central)
  5. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma. Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN (2014) Exp Hematol 42(1): 39-45
    › Primary publication · 24096123 (PubMed) · PMC5002948 (PubMed Central)
  6. Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategy. Ragon BK, Clifton C, Chen H, Savani BN, Engelhardt BG, Kassim AA, Vaughan LA, Lucid C, Jagasia M (2014) Biol Blood Marrow Transplant 20(1): 53-7
    › Primary publication · 24120525 (PubMed)
  7. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Das-Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Jagasia M (2014) Haematologica 99(11): 1746-52
    › Primary publication · 25150260 (PubMed) · PMC4222474 (PubMed Central)
  8. New allergies after cord blood transplantation. Vaughan LA, Vu M, Sengsayadeth S, Lucid C, Clifton C, McCarty K, Hagaman D, Domm J, Kassim A, Chinratanalab W, Goodman S, Greer J, Frangoul H, Engelhardt BG, Jagasia M, Savani BN (2013) Cytotherapy 15(10): 1259-65
    › Primary publication · 23993300 (PubMed)
  9. Necrotising enterocolitis is characterised by disrupted immune regulation and diminished mucosal regulatory (FOXP3)/effector (CD4, CD8) T cell ratios. Weitkamp JH, Koyama T, Rock MT, Correa H, Goettel JA, Matta P, Oswald-Richter K, Rosen MJ, Engelhardt BG, Moore DJ, Polk DB (2013) Gut 62(1): 73-82
    › Primary publication · 22267598 (PubMed) · PMC3606820 (PubMed Central)
  10. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G (2013) Biol Blood Marrow Transplant 19(7): 1129-33
    › Primary publication · 23623892 (PubMed)